DHODH and neuroblastoma: Given that single-agent DHODH inhibition was not curative in the xenograft and transgenic in vivo models of neuroblastoma, we next sought to combine brequinar with the standard-of-care chemotherapy temozolomide, a DNA alkylating agent, which is the backbone of treatment in relapsed and refractory neuroblastoma (33).